#211
|
||||
|
||||
Ñïàñèáî, êîëëåãè. Âîò òàê âñåãäà - ñìûñë ÿñåí, à "êàê ýòî áóäåò ïî-ðóññêè".. "àíàëèçèðóåòñÿ íà ïðîòÿæåíèè âñåé æèçíè" - ýòî ñêîðåå ê ñìûñëó, ÷åì "ïî-ðóññêè", ÈÌÕÎ Ðå÷ü èäåò î ìîäåëè ðàñ÷åòà ôàðìàêîýêîíîìè÷åñêîé ýôôåêòèâíîñòè ëå÷åíèÿ èñõîäÿ èç îæèäàåìîé ïðîäîëæèòåëüíîñòè æèçíè.
__________________
Àííà, âðà÷-ýíäîêðèíîëîã Âîðîíåæ, êëèíèêà Íåïëàöåáî |
#212
|
|||
|
|||
Ëó÷øå áû êîíå÷íî [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] Åùå ëó÷øå êîíå÷íî áû ïîëíûé.
|
#213
|
||||
|
||||
Äà, ýòî îíî, Øåðëîê. ß, ïðàâäà, áðàëà èç ìåäñêåéïà òåêñò, ñëîâà íåìíîãî äðóãèå, íî ñìûñë òîò æå.
__________________
Àííà, âðà÷-ýíäîêðèíîëîã Âîðîíåæ, êëèíèêà Íåïëàöåáî |
#214
|
|||
|
|||
lifetime analytic horizon
Ànalytic horizon the period of time after an intervention ends, during wich cost and outcomes accrue and are measured. Áûâàåò êðàòêîñðî÷íûé, êîãäà âàæíûå ðåçóëüòàòû ìîãóò áûòü èçìåðåíû â êîðîòêîå âðåìÿ. Ïîýòîìó ïåðåâåëà áû "ïðîäîëæèòåëüíîñòü (âðåìÿ ñóùåñòâîâàíèÿ) àíàëèòè÷åñêîãî ãîðèçîíòà" |
#215
|
|||
|
|||
"Àíàëèòè÷åñêèé ïåðèîä" ÷òî-ëè, "àíàëèòè÷åñêèé ïåðèîä â òå÷åíèè/íà ïðîòÿæåíèè âñåé æèçíè". Âîò òóò åùå ïðî ýòî [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
Öèòàòà:
|
#216
|
|||
|
|||
Ïðîñòî äëÿ îòçûâ÷èâûõ ïîìîùíèêîâ.
"For some strange reason the general opinion among doctors is that if one writes a book he must have superior knowledge of the subject. Since no one troubles to read the book the delusion is not discovered."
(--Arthur E. Hertzler, 1870-1946) “We know that many practicing physicians are not using well proven interventions or implementing well-publicized national guidelines. The legal definition of standard of care protects these physicians and encourage them to change slowly, if at all.” (--Daniel Merenstein) “In America…when a patient asks you to take care of her, you will do everything within your power to cure her disease. Failing that, you will do everything within your power to prolong her life. And failing that, you will do everything within your power to relieve her suffering. The problem with that ethic is the world “everything”. Everything may be unnecessary. (--Alan Robert Spievack) |
#217
|
|||
|
|||
Äîáðûé âå÷åð!
Ïðîäîëæèì? :-) Several large randomized trials that have compared commonly prescribed platinum doublets did not support any specific regimen as the evidenced-based practice standard for NSCLC Ñîáñòâåííî, èíòåðåñóåò "êðàñèâû" ïåðåâîä íà ðóññêèé âûäåëåííîãî öâåòîì... lack overlapping toxic effects - íåñîâïàäåíèå ïðîôèëåé òîêñè÷íîñòè? |
#218
|
|||
|
|||
as the evidenced-based practice standard - êàê äîêàçàííûé ñòàíäàðò ïðèìåíåíèÿ äëÿ ëå÷åíèÿ NSCLC
lack overlapping toxic effects - îòñóòñòâèå ñîâìåùåííûõ òîêñè÷åñêèõ ýôôåêòîâ doublets - ïàðíàÿ/äóáëåò õèìèîòåðàïèÿ. |
#219
|
||||
|
||||
lack overlapping toxic effects - ìíå êàæåòñÿ, "ñîâìåùåííûõ òîêñè÷åñêèõ ýôôåêòîâ" êàê-òî íå î÷åíü. Íå çâó÷èò îáîðîò "ñîâìåùåííûå òîêñè÷åñêèå ýôôåêòû". Òî åñòü overlapping êàê "ñîâìåùåíèå", "íàëîæåíèå", "ïåðåõëåñò", ìíå êàæåòñÿ, íàäî ïåðåâîäèòü êàê "îòñóòñòâèå íàëîæåíèÿ (ñóììèðîâàíèÿ) òîêñè÷åñêèõ ýôôåêòîâ".
__________________
Èëþõèí Åâãåíèé Àðêàäüåâè÷ |
#220
|
|||
|
|||
Ñïàñèáî çà ïðåäëîæåíèÿ!
Åù¸ âîò, ñêîðåå â òåðìèíîëîãèþ íàäî áóäåò çàòåì - TTP curves were constructed using the Kaplan–Meier product limit method À çäåñü ïðîñòî ïîíðàâèëîñü îáúåäèíåíèå â îäíîì ïðåäëîæåíèè ïàðàìåòðîâ ñðàâíåíèÿ: Within the ITT population, 17.1% had brain metastases and 12.2% were African-American. |
#221
|
|||
|
|||
the Kaplan–Meier product limit method - ìåòîä Êàïëàí-Ìàéåðà èëè ìåòîä ðàñ÷åòà ïðîèçâåäåíèÿ ïðåäåëîâ/èíòåðâàëüíûõ ïîêàçàòåëåé
Kaplan-Meier Product-Limit Estimator Rather than classifying the observed survival times into a life table, we can estimate the survival function directly from the continuous survival or failure times. Intuitively, imagine that we create a life table so that each time interval contains exactly one case. Multiplying out the survival probabilities across the "intervals" (i.e., for each single observation) we would get for the survival function: êàðòèíêó ñ ôîðìóëîé íå ïîëó÷èëîñü âñòàâèòü, ïîýòîìó ïðîäîëæåíèå çäåñü [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] Íà ðóññêîì ñòàòüÿ î ìåòîäå Êàïëàí-Ìàéåðà [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] |
#222
|
|||
|
|||
From the Lymphoma Disease Management Team.... Memorial Sloan-Kettering Cancer Center
Failure-free survival - ? Ñîáñòâåííî ãîâîðÿ, ýòî âåäü äîëæíà áûòü "âûæèâàåìîñòü áåç ïðîãðåññèðîâàíèÿ"? Íî â ñòàòüå îäíîâðåìåííî óïîìèíàþòñÿ îáà òåðìèíà. È ðàñøèôðîâêè, ÷òî ïîä ýòèì ïîíèìàåòñÿ, ïîêà íå óâèäåë (â ñàìîé ñòàòüå). While the Italian study was criticized for design flaws and conduct of the Stanford V arm, particularly with regard to the radiotherapy (RT) component, some indicated that Stanford V might not be effective outside its site of design and expertise. Ñòýíôîðä-5 ìîæåò áûòü íåýôôåêòèâíîé âíå ñòåí ó÷ðåæäåíèÿ, ãäå áûëà ðàçðàáîòàíà è îïðîáîâàíà? :-) |
#223
|
|||
|
|||
Òàê, Failure-free survival îïðåäåëèëè:
FFS was defined as time from start of treatment to last follow-up or disease progression, any post-treatment response less than CR, relapse, or death from any cause. |
#224
|
||||
|
||||
À ëàòûíü åùå êòî-íèáóäü ïîìíèò?
Íóæíî ïåðåâåñòè âîò òàêîé òåêñò 19 âåêà: "Taenia microsoma mihi. T. capitis varii osculis magnis, rostello elongato subclavato, collo et articulis omnibus brevissimis, his obtusis, lemniscis marginalibus, unilateralibus. Hab. Am. Hornschuch copiam speciminum a Scillingio in itest. Anatis mollissimae anno 1823. detectam et postmodum specimina iterum multa ibidem ab eodem d. 16 Januarii 1826. inventa benevole transmisit. Descr. Longitudo a quarta pollicis parte usque ad semipollicem cicriter aequat. Latitudo exigua, ut vermiculi filis aemulentur. Color albus. Caput subtilissimum, ut nudo oculo meo discernere in non valerem, subconicum, interdum etiam transverse ellipticum, osculi quatuor magnis, oblongis visis, lateralibus, et rostello quam caput longiore, tenuissimo, ad apicem crassum sensim aucto, inermi, instructum. Collum capite tenuis, eidem longitudine aequale, aut idem, sed vix bis superans. Articuli omnes tam subtiles, quos nec lente simplici, nec duplici usus distinguere potuerim, brevissimi, obtusi; primi collo latitudine aequales, sensim increscunt, ultimus more solito est rotundatus, obtusus. Lemnisci marginales, cylindrici aut interdum subclavati, unilaterales, ordino incerto positi, magnam partem articulorum, anterioribus exceptis, ornant, non in omnibus vero speciminibus adsunt." Íàâåðíîå, ìîæíî è ÷åðåç Ïðîìïò ïðîãíàòü - ó íàñ åãî íåò è íå ðàçðåøàþò ñòàâèòü. Íî Ïðîìïò ñòàðûå òåêñòû ïåðåâîäèò î÷åíü ñòðàííî.
__________________
Åëåíà Åâãåíüåâíà Êîðíàêîâà, ïàðàçèòîëîã. |
#225
|
|||
|
|||
Ñòèëèñòè÷åñêèå îøèáêè èñïðàâëÿéòå ñàìè.
Öèòàòà:
Öèòàòà:
|